Strategies and prospects for chlamydial mRNA vaccines
JIN Ying-qi1,2, WANG Zong-bao2, WANG Chuan1
1. Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang 421001, China; 2. Institute of Cell and Genetics, Hengyang Medical College, University of South China, Hengyang 421001, China
Abstract：Chlamydia are obligate intracellular, multi-host pathogens that can infect regions including the ocular mucosa, respiratory tract and urogenital tract, thus causing a variety of infectious diseases and complications in humans and animals. However, Chlamydia usually present an insidious infection with a long incubation period, and show mild or even asymptomatic clinical symptoms. After antibiotic treatment, the infection often persists and may recur or heal slowly, thus posing a serious health threat. Therefore, developing safe and efficient vaccines is an effective method to prevent and treat chlamydial infectious diseases. mRNA vaccines have emerged in recent years, and are widely used against viral and infectious pathogens. Compared with whole bacteria vaccines, subunit vaccines and DNA vaccines, mRNA vaccines not only have advantages in aspects including their safety, immunity and flexibility, as well as their ability to prevent infectious diseases. In this review, we summarize the relevant research and important findings on Chlamydia and mRNA vaccines, and we systematically introduce the processes to develop chlamydial mRNA vaccines, including antigens and adjuvants, antigen delivery and immunization. Our aim is to provide design ideas and a theoretical basis for the development of safe and effective chlamydial mRNA vaccines.
金盈圻, 王宗保, 王川. 衣原体mRNA疫苗的研发对策与展望[J]. 中国人兽共患病学报, 2022, 38(4): 349-358.
JIN Ying-qi, WANG Zong-bao, WANG Chuan. Strategies and prospects for chlamydial mRNA vaccines. Chinese Journal of Zoonoses, 2022, 38(4): 349-358.
[1] Malhotra M, Sood S, Mukherjee A, et al.Genital Chlamydia trachomatis: an update[J]. Indian J Med Res, 2013, 138(3): 303-316. [2] Elwell C, Mirrashidi K, Engel J.Chlamydia cell biology and pathogenesis[J]. Nat Rev Microbiol, 2016, 14(6): 385-400. DOI: 10.1038/nrmicro.2016.30 [3] Chu J, Yarrarapu SNS, Durrani MI.Psittacosis [M]. Statpearls Treasure Island(FL):StatPearls Publishing,2021. [4] Vanrompay D, Ducatelle R, Haesebrouck F.Chlamydia psi-ttaci infections: a review with emphasis on avian chlamydiosis[J]. Vet Microbiol, 1995, 45(2/3): 93-119. DOI: 10.1016/0378-1135(95)00033-7 [5] Ojeda Rodriguez JA, Modi P, Brady MF.Psittacosis pneumonia [M]. Statpearls Treasure Island(FL):StatPearls Publishing,2021. [6] Stewardson AJ, Grayson ML.Psittacosis[J]. Infect Dis Clin North Am, 2010, 24(1): 7-25. DOI: 10.1016/j.idc.2009.10.003 [7] Ross J. mRNA stability in mammalian cells[J]. Microbiol Rev, 1995, 59(3): 423-450. DOI: 10.1128/mr.59.3.423-450.1995 [8] Zhang C, Maruggi G, Shan H, et al.Advances in mRNA vaccines for infectious diseases[J]. Front Immunol, 2019, 10: 594. DOI: 10.3389/fimmu.2019.00594 [9] Pascolo S.Vaccination with messenger RNA[J]. Methods Mol Med, 2006, 127: 23-40. DOI: 10.1385/1-59745-168-1:23 [10] Geall AJ, Verma A, Otten GR, et al.Nonviral delivery of self-amplifying RNA vaccines[J]. Proc Natl Acad Sci U S A, 2012, 109(36): 14604-14609. DOI: 10.1073/pnas.1209367109 [11] Brito LA, Chan M, Shaw CA, et al.A cationic nanoemulsion for the delivery of next-generation RNA vaccines[J]. Mol Ther, 2014, 22(12): 2118-2129. DOI: 10.1038/mt.2014.133 [12] Leitner WW, Hwang LN, deVeer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways[J]. Nat Med, 2003, 9(1): 33-39. DOI: 10.1038/nmxx [13] Pulendran B, Ahmed R.Translating innate immunity into immunological memory: implications for vaccine development[J]. Cell, 2006, 124(4): 849-863. DOI: 10.1016/j.cell.2006.02.019 [14] Yu H, Karunakaran KP, Kelly I, et al.Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells[J]. J Immunol, 2011, 186(6): 3615-3621. DOI: 10.4049/jimmunol.1002952 [15] Mabey DC, Hu V, Bailey RL, et al.Towards a safe and effective chlamydial vaccine: lessons from the eye[J]. Vaccine, 2014, 32(14): 1572-1578. DOI: 10.1016/j.vaccine.2013.10.016 [16] Farris CM, Morrison SG, Morrison RP.CD4+T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection[J]. Infect Immun, 2010, 78(10): 4374-4383. DOI: 10.1128/IAI.00622-10 [17] Abraham S, Juel HB, Bang P, et al.Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Infect Dis, 2019, 19(10): 1091-1100. DOI: 10.1016/S1473-3099(19)30279-8 [18] 夏敏, 杨晓岚, 杨鹏辉, 等. 结核分枝杆菌Ag85B-mRNA疫苗的体外合成及其免疫原性研究[J]. 免疫学杂志, 2019, 35(5): 404-8. DOI:10.13431/j.cnki.immunol.j.20190061 [19] Schautteet K, Stuyven E, Beeckman DS, et al.Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa[J]. Vaccine, 2011, 29(7): 1399-1407. DOI: 10.1016/j.vaccine.2010.12.042 [20] Brisse M, Vrba SM, Kirk N, et al.Emerging concepts and technologies in vaccine development[J]. Front Immunol, 2020, 11: 583077. DOI: 10.3389/fimmu.2020.583077 [21] Ho W, Gao M, Li F, et al.Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery[J]. Adv Healthc Mater, 2021, 10(8): e2001812. DOI: 10.1002/adhm.202001812 [22] Pardi N, Hogan MJ, Porter FW, et al.mRNA vaccines - a new era in vaccinology[J]. Nat Rev Drug Discov, 2018, 17(4): 261-279. DOI: 10.1038/nrd.2017.243 [23] Jackson NAC, Kester KE, Casimiro D, et al.The promise of mRNA vaccines: a biotech and industrial perspective[J]. NPJ Vaccines, 2020, 5: 11. DOI: 10.1038/s41541-020-0159-8 [24] Zeng C, Zhang C, Walker PG, et al.Formulation and delivery technologies for mRNA vaccines[J]. Curr Top Microbiol Immunol, 2020,2:10. DOI: 10.1007/82_2020_217 [25] Ertl PF, Thomsen LL.Technical issues in construction of nucleic acid vaccines[J]. Methods, 2003, 31(3): 199-206. DOI: 10.1016/s1046-2023(03)00134-8 [26] Phillips S, Quigley BL, Timms P.Seventy years of Chlamydia vaccine research-limitations of the past and directions for the future[J]. Front Microbiol, 2019, 10: 70. DOI: 10.3389/fmicb.2019.00070 [27] Brito LA, Kommareddy S, Maione D, et al.Self-amplifying mRNA vaccines[J]. Adv Genet, 2015, 89: 179-233. DOI: 10.1016/bs.adgen.2014.10.005 [28] Deering RP, Kommareddy S, Ulmer JB, et al.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines[J]. Expert Opin Drug Deliv, 2014, 11(6): 885-899. DOI: 10.1517/17425247.2014.901308 [29] Vogel AB, Lambert L, Kinnear E, et al.Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses[J]. Mol Ther, 2018, 26(2): 446-455. DOI: 10.1016/j.ymthe.2017.11.017 [30] Maruggi G, Zhang C, Li J, et al.mRNA as a transformative technology for vaccine development to control infectious diseases[J]. Mol Ther, 2019, 27(4): 757-772. DOI: 10.1016/j.ymthe.2019.01.020 [31] Baehr W, Zhang YX, Joseph T, et al.Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes[J]. Proc Natl Acad Sci U S A, 1988, 85(11): 4000-4004. DOI: 10.1073/pnas.85.11.4000 [32] Liang S, Bulir D, Kaushic C, et al.Considerations for the rational design of a Chlamydia vaccine[J]. Hum Vaccin Immunother, 2017, 13(4): 831-5. DOI: 10.1080/21645515.2016.1252886 [33] ZHang T, Li H, Lan X, et al.The bioinformatics analyses reveal novel antigen epitopes in major outer membrane protein of Chlamydia trachomatis[J]. Indian J Med Microbiol, 2017, 35(4): 522-528. DOI: 10.4103/ijmm.IJMM_17_251 [34] Olsen AW, Follmann F, Erneholm K, et al.Protection Against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein[J]. J Infect Dis, 2015, 212(6): 978-989. DOI: 10.1093/infdis/jiv137 [35] Pal S, Cruz-Fisher MI, Cheng C, et al.Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge[J]. NPJ Vaccines, 2020, 5: 90. DOI: 10.1038/s41541-020-00239-7 [36] Li Z, Chen D, Zhong Y, et al.The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells[J]. Infect Immun, 2008, 76(8): 3415-3428. DOI: 10.1128/IAI.01377-07 [37] Zhong G.Chlamydial plasmid-dependent pathogenicity[J]. Trends Microbiol, 2017, 25(2): 141-152. DOI: 10.1016/j.tim.2016.09.006 [38] Zhou H, Huang Q, Li Z, et al.PORF5 plasmid protein of Chlamydia trachomatis induces MAPK-mediated pro-inflammatory cytokines via TLR2 activation in THP-1 cells[J]. Sci China Life Sci, 2013, 56(5): 460-466. DOI: 10.1007/s11427-013-4470-8 [39] Li Z, Wang S, Wu Y, et al.Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice[J]. Sci China C Life Sci, 2008, 51(11): 973-980. DOI: 10.1007/s11427-008-0130-9 [40] Vasilevsky S, Stojanov M, Greub G, et al.Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates[J]. Virulence, 2016, 7(1): 11-22. DOI: 10.1080/21505594.2015.1111509 [41] Crane DD, Carlson JH, Fischer ER, et al.Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen[J]. Proc Natl Acad Sci U S A, 2006, 103(6): 1894-1899. DOI: 10.1073/pnas.0508983103 [42] Tan C, Hsia RC, Shou H, et al.Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family[J]. Infect Immun, 2009, 77(8): 3218-3226. DOI: 10.1128/IAI.01566-08 [43] Yu H, Karunakaran KP, Jiang X, et al.Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice[J]. Vaccine, 2014, 32(36): 4672-4680. DOI: 10.1016/j.vaccine.2014.06.002 [44] Liu S, Sun W, Chu J, et al.Construction of recombinant HVT expressing PmpD, and immunological evaluation against Chlamydia psittaci and marek?s disease virus[J]. PLoS One, 2015, 10(4): e0124992. DOI: 10.1371/journal.pone.0124992 [45] Luan X, Peng B, Li Z, et al.Vaccination with MIP or Pgp3 induces cross-serovar protection against chlamydial genital tract infection in mice[J]. Immunobiology, 2019, 224(2): 223-230. DOI: 10.1016/j.imbio.2018.11.009 [46] Paes W, Brown N, Brzozowski AM, et al.Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice[J]. Vaccine, 2016, 34(35): 4123-4131. DOI: 10.1016/j.vaccine.2016.06.081 [47] Karunakaran KP, Yu H, Jiang X, et al.Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine[J]. Vaccine, 2015, 33(18): 2159-2166. DOI: 10.1016/j.vaccine.2015.02.055 [48] Zhong G, Brunham RC, de la Maza LM, et al. National institute of allergy and infectious diseases workshop report: ＂Chlamydia vaccines: the way forward＂[J]. Vaccine, 2019, 37(50): 7346-7354. DOI: 10.1016/j.vaccine.2017.10.075 [49] Kowalski PS, Rudra A, Miao L, et al.Delivering the messenger: advances in technologies for therapeutic mRNA delivery[J]. Mol Ther, 2019, 27(4): 710-728. DOI: 10.1016/j.ymthe.2019.02.012 [50] Stanton MG.Current status of messenger RNA delivery systems[J]. Nucleic Acid Ther, 2018, 28(3): 158-165. DOI: 10.1089/nat.2018.0726 [51] Zhuang X, Qi Y, Wang M, et al.mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice[J]. Vaccines (Basel), 2020, 8(1):123. DOI: 10.3390/vaccines8010123 [52] Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís Má. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles[J]. Int J Nanomedicine, 2014, 9: 1833-1843. DOI: 10.2147/IJN.S39810 [53] Guimarães LE, Baker B, Perricone C, et al.Vaccines, adjuvants and autoimmunity[J]. Pharmacol Res, 2015, 100: 190-209. DOI: 10.1016/j.phrs.2015.08.003 [54] Thoma C.First chlamydia vaccine trial in humans[J]. Nat Rev Urol, 2019, 16(10): 566. DOI: 10.1038/s41585-019-0232-0 [55] Van Lint S, Wilgenhof S, Heirman C, et al.Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula[J]. Cancer Immunol Immunother, 2014, 63(9): 959-967. DOI: 10.1007/s00262-014-1558-3 [56] Weissman D, Ni H, Scales D, et al.HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response[J]. J Immunol, 2000, 165(8): 4710-4717. DOI: 10.4049/jimmunol.165.8.4710 [57] Midoux P, Pichon C.Lipid-based mRNA vaccine delivery systems[J]. Expert Rev Vaccines, 2015, 14(2): 221-234. DOI: 10.1586/14760584.2015.986104 [58] Petsch B, Schnee M, Vogel AB, et al.Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection[J]. Nat Biotechnol, 2012, 30(12): 1210-1216. DOI: 10.1038/nbt.2436 [59] Schlake T, Thess A, Fotin-Mleczek M, et al.Developing mRNA-vaccine technologies[J]. RNA Biol, 2012, 9(11): 1319-1330. DOI: 10.4161/rna.22269 [60] Van Lint S, Renmans D, Broos K, et al.The ReNAissanCe of mRNA-based cancer therapy[J]. Expert Rev Vaccines, 2015, 14(2): 235-251. DOI: 10.1586/14760584.2015.957685 [61] Xu S, Yang K, Li R, et al.mRNA vaccine era-mechanisms, drug platform and clinical prospection[J]. Int J Mol Sci, 2020, 21(18):6582. DOI: 10.3390/ijms21186582 [62] 杨建宏, 买亚萍, 郭珏铄, 等. 一种阳离子脂质体-鱼精蛋白-mRNA肿瘤疫苗及其制备方法和应用方法, CN110882383A [P]. [63] Islam MA, Rice J, Reesor E, et al.Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice[J]. Biomaterials, 2021, 266: 120431. DOI: 10.1016/j.biomaterials.2020.120431 [64] Smits EL, Cools N, Lion E, et al.The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells[J]. Cancer Immunol Immunother, 2010, 59(1): 35-46. DOI: 10.1007/s00262-009-0721-8 [65] Kreiter S, Diken M, Selmi A, et al.FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines[J]. Cancer Res, 2011, 71(19): 6132-6142. DOI: 10.1158/0008-5472.CAN-11-0291 [66] Shakya AK, Chowdhury MYE, Tao W, et al.Mucosal vaccine delivery: Current state and a pediatric perspective[J]. J Control Release, 2016, 240: 394-413. DOI: 10.1016/j.jconrel.2016.02.014 [67] Li M, Li Y, Peng K, et al.Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses[J]. Acta Biomater, 2017, 64: 237-248. DOI: 10.1016/j.actbio.2017.10.019 [68] Andersen AA, Van Deusen RA.Production and partial characterization of monoclonal antibodies to four Chlamydia psittaci isolates[J]. Infect Immun, 1988, 56(8): 2075-2079. DOI: 10.1128/iai.56.8.2075-2079.1988 [69] Kraan H, Vrieling H, Czerkinsky C, et al.Buccal and sublingual vaccine delivery[J]. J Control Release, 2014, 190: 580-592. DOI: 10.1016/j.jconrel.2014.05.060 [70] Stary G, Olive A, Radovic-Moreno AF, et al. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells [J]. Science, 2015, 348(6241): aaa8205. DOI: 10.1126/science.aaa8205 [71] Brunham RC.A Chlamydia vaccine on the horizon[J]. Science, 2015, 348(6241): 1322-1323. DOI: 10.1126/science.aac6528 [72] Yu H, Karunakaran KP, Jiang X, et al.Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis[J]. Expert Rev Vaccines, 2016, 15(8): 977-988. DOI: 10.1586/14760584.2016.1161510 [73] Lindsay KE, Vanover D, Thoresen M, et al.Aerosol delivery of synthetic mRNA to vaginal mucosa leads to durable expression of broadly neutralizing antibodies against HIV[J]. Mol Ther, 2020, 28(3): 805-819. DOI: 10.1016/j.ymthe.2020.01.002 [74] Van Lint S, Renmans D, Broos K, et al.Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells[J]. Cancer Immunol Res, 2016, 4(2): 146-156. DOI: 10.1158/2326-6066.CIR-15-0163 [75] Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al.Factors affecting the absorption of subcutaneously administered insulin: effect on variability[J]. J Diabetes Res, 2018, 2018: 1205121. DOI: 10.1155/2018/1205121 [76] Moyer TJ, Zmolek AC, Irvine DJ.Beyond antigens and adjuvants: formulating future vaccines[J]. J Clin Invest, 2016, 126(3): 799-808. DOI: 10.1172/JCI81083 [77] Sahin U, Muik A, Derhovanessian E, et al.COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses[J]. Nature, 2020, 586(7830): 594-599. DOI: 10.1038/s41586-020-2814-7
2022, Vol. 38 
